Novartis snags Saatchi & Saatchi
This article was originally published in The Tan Sheet
Executive Summary
Novartis has selected Publicis Group's Saatchi & Saatchi unit as the advertising agency for its Consumer Health division. Triaminic and Theraflu are the two major cough/cold brands included in the deal, Saatchi & Saatchi said. The advertising firm worked on McNeil Consumer & Specialty Pharmaceuticals' Tylenol, Pepcid AC andMylanta brands for several years before the accounts were passed on to Deutsch and Alchemy in late 2003 (1"The Tan Sheet" Dec. 8, 2003, In Brief)...
You may also be interested in...
McNeil advertising
Tylenol advertising account, reportedly valued at $100 mil., has been awarded to Deutsch (New York), McNeil Consumer & Specialty Pharmaceuticals announces Nov. 26. Deutsch also received St. Joseph's aspirin account, valued at more than $20 mil. Accounts for heartburn OTCs Pepcid AC ($48 mil.) and Mylanta ($16 mil.) went to Alchemy, which, like Deutsch, is owned by Interpublic group. All accounts were previously handled by New York-based Saatchi & Saatchi, which developed new Maximum Strength Pepcid AC ads that broke Nov. 24...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.